About

Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.

These diseases include Retinitis Pigmentosa, Dry Age-related Macular Degeneration (AMD), and Stargardt Disease. We are developing a proprietary platform technology, employing ambient light-sensitive Multi-Characteristic Opsins (MCO) that has potential to treat a broad range of genetic illnesses.

Nanoscope Therapeutics, Inc.
1312 Brown Trail, Suite A
Bedford, TX 76022
(817) 857-1186
  • Dr. Al Guillem | Chairman of the Board

    Dr. Al Guillem, Chairman of the Board, is a veteran of the pharmaceutical industry with nearly 40 years of leadership experience in bringing new therapies to the market and readying pharmaceutical manufacturing facilities for commercial production at both well-established and startup companies. Al holds a BSc in Chemistry from the University of Mary Washington and a PhD in Chemistry from Virginia Commonwealth University. Al brings a deep knowledge and insight into pharmaceutical manufacturing across many dosage forms and manufacturing operations. Heheld senior positions at Genzyme/Bone Care, Wyeth (Pfizer), ad Boeringher Ingelheim, as well as at start-up companies such as Medeva Americas and Adams Respiratory Therapeutics (ARXT), where he, along with other team members, brought the Mucinex product line to the market. ARXT sold to Reckitt Benckiser for $2.3 billion in 2007. Most recently, Al co-founded and held the role of President and CEO of ZS Pharma, a start-up company developing a product for hyperkalemia or high levels of potassium in the blood. ZS Pharma was sold to Astra Zeneca in 2015 for $2.7 billion.

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) has decades of Biomedical Technologies experience  in Asia, Europe and USA.  He has authored over 200 publications and patents.  He is the Primary Investigator for major grants from National Eye Institute including  Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award.

  • Sulagna Bhattacharya |  Co-Founder & CEO

    Sulagna Bhattacharya has decades of experience in management consulting with specialties in business Intelligence and risk management. Her expertise includes market research, product and business development, planning including budgeting and forecasting. She played a key role in seven full life cycle project implementations including two merger acquisitions. She has authored multiple publications and patents. She is winner of Healthcare Heroes award in 2019.
  • Mohamed A. Genead, MD, MBA | Chief Development Officer & Chief Medical Officer

    A serial life-sciences entrepreneur, senior innovative biopharma executive, inventor, and consultant to many ophthalmic biotechnology companies and healthcare venture firms. A global executive and senior leader with 20-plus years’ experience in biopharmaceutical drug, business development, and corporate strategies execution from discovery to late development and commercial phases. Played key roles at executing launches and drove sales growth in country, regional, and global development positions together with teams of direct reports. Critical team member to negotiate and manage the partnership between biopharma and strategics to expand ophthalmology developments.

    Co-founder of several start-ups and being instrumental in the raising of over $500M in venture and institutional capital for numerous life sciences biotech companies. A board member of several ophthalmic organizations and scientific advisory board. Excellent academic background, including extensive research and clinical experience at top-tier academic and medical institutions.

    Most recently, Dr. Genead co-founded Aviceda, a late-stage pre-clinical biotechnology company leveraging disruptive nanoparticles-based therapy and technology platform to cure ocular inflammatory, neurodegenerative, and fibrovascular system diseases. Under his leadership as Chief Executive Officer, Aviceda attained a best-in-class valuation percentile. Prior to that, Dr. Genead served as Chief Medical Officer and Executive Vice-President for GenSight Biologics, a publicly traded company, where he led the clinical development and medical affairs organization in launching multiple phase I-III trials leveraging a disruptive ocular gene therapy and optogenetics platforms for patients with ocular degenerative diseases. Prior to GenSight, Dr. Genead led Biogen’s Ophthalmology and Ocular gene therapy franchise in collaborations with Dr. Jean Bennett, MD, PhD at University of Pennsylvania (Inventor of Gene therapy [Luxturna] for LCA scientific foundation of Spark Therapeutics) and AGTC partnerships in the execution of multiple retina gene therapy programs intended for regulatory approvals of ophthalmic gene therapy products.

    Prior to joining the pharmaceutical industry, Dr. Genead spent years in academic medicine serving as physician-scientist, co-director of center of Retina Degenerative Diseases and as an Investigator in the Department of Ophthalmology and Visual Sciences, at the University of Illinois in Chicago. His area of academic interest focused on novel retinal therapeutics ranging from ocular gene therapy to retina regenerative stem-cell therapies for orphan retina diseases such as Stargardt disease and retinitis pigmentosa. His team pioneered the use of topical eye drops for treatment of macular edema associated with retinal dystrophies. He discovered a new gene mutation in patients afflicted with Leber’s congenital amaurosis in collaboration with researchers at McGill University. He was the primary and key author for numerous peer-reviewed manuscripts in highly impact factor scientific journals (more than 150 manuscripts and presentations) focusing on clinical research and novel therapeutics.

    Dr. Genead completed his vitreoretinal fellowship and residency at the Department of Ophthalmology and Visual Sciences of the University of Illinois in Chicago and Medical College of Wisconsin.

  • Anthony T. Togba, CPA, CGMA | CFO

    Anthony T. Togba has about 30 years of professional experience in finance, banking, insurance and accounting. He began his career in public accounting and he has held several leadership positions including former President/CEO of Meridien BIAO Bank (Liberia) Limited. Anthony is a CPA licensed in Texas. He is also a Certified Global Management Accountant (CGMA) and holds an MBA from the Arizona State University. He is a member of the American Institute of Certified Public Accountants and the Texas Society of CPAs.

     

     

  • Michelle Carpenter  |  VP Regulatory Affairs

    Ms. Carpenter is a senior management leader and regulatory advisor with more than 25 years of experience gaining global approvals for drugs and biologics for companies ranging from start-up to Fortune 500.  She has a keen interest in developing treatments for orphan diseases and has extensive experience in ophthalmology (neovascular and dry macular degeneration, Stargardt Disease) and gene therapy (neovascular macular degeneration, sickle cell disease).  Ms. Carpenter has held numerous Senior/Vice President roles in Regulatory Affairs, Quality Affairs and Project Management and has worked at True North and Afferent Pharmaceuticals, Sanofi, Santen, and Merck.  She also teaches Regulatory Affairs certification courses for the UC Santa Cruz Bioscience Program and has managed a successful consulting firm.  She earned her Juris Doctorate, with emphasis in Health Law and Ethics, from Golden Gate University and Bachelor’s degree from University of California at Santa Barbara.

  • Hayley Lane  |  VP Clinical Operations

    Ms. Lane has over 25 years of experience in the Pharma/Biotech industry in clinical operations and project management. She has served as VP of Clinical Operations at Adverum Biotechnologies and has held leadership positions at Genentech, Avalanche, Geron, Pfizer and Sanofi.

  • Anil Lalwani | VP CMC and Quality

    Anil Lalwani has over 25 years of technical, CMC-centric industry experience with a focus on phase-appropriate products development that meets or exceeds contemporary regulatory expectations. He leveraged his industry experience in academia to help translational (bench-to-clinic) programs with CMC, QA, and FDA engagement for autologous cell therapy and implantable neuromodulation devices for spinal cord injury and pain, a gene therapy (AAV2) for retinal dystrophy (LHON), and allogeneic bone marrow and umbilical cord-derived mesenchymal stem cell products for neurological diseases.

    Anil’s recent regulatory CMC experiences at Allergan (now AbbVie) on a CRISPR/Cas9 gene therapy program, his track record, and his passion for helping unmet need patients adds depth and breadth to Nanoscope’s growing team and portfolio.

    Anil holds a BSc in Mechanical Engineering from Rutgers University, an MSc in Biotechnology Engineering from the University of Pennsylvania, and an MBA in Health Care from the University of Miami.

  • Dr. Kissaou Tchedre | Director of Biopharmaceutical Operations

    Dr. Kissaou Tchedre is Director of Biopharmaceutical Operations at Nanoscope, supporting our Development programs on Gene therapy from preclinical to clinical studies. He has management responsibilities for manufacturing and analytical operations. He is a Biomedical Scientist with decades of experience in commercial Occular Medical Device development at Menicon, a Japanese pharma/medical devices company. He got his MS in molecular biology and a PhD in Biomedical Sciences at the UNTHSC.

    Dr. Tchedre did his post doc at Schepens Eye Research Institute at Harvard Medical School. He has international R&D and business experience in Japan, France and Switzerland.

  • Dr. Ananta Ayyagari | Director of IP and Project Manager

    Dr. Ananta Ayyagari is Director of IP and Project Manager at Nanoscope, supporting our Intellectual Property Development and managing vision restoration projects working closely with preclinical, clinical, CMC and regulatory teams. After completing her doctoral degree in Chemistry, Dr. Ayyagari carried out Postdoctoral fellowship at the Georgia Institute of Technology and the University of Wisconsin-Madison. Her expertise includes development of methods for drug and gene delivery. She has authored several papers and patents.

  • Dr. Subrata Batabyal | Director of Non-clinical Development

    Dr. Subrata Batabyal is Director of Non-clinical Development, leading the pre-clinical research and assay development for Nanoscope’s gene therapy platforms. He earned a PhD in Chemistry investigating biomolecular interactions, followed by Postdoctoral research in biophotonics, focused on optogenetics, gene delivery and optical detection of neuronal activation. He has authored several key papers on cell and gene therapy.

  • John Koester | Global Head of Biostatistics and Clinical Data Management

    Mr. Koester has over 30 years of experience in the pharmaceutical industry. He has worked in ophthalmology clinical development for most of his career and has been a key team member of numerous successful NDAs in wet AMD, glaucoma, ocular allergy, ocular inflammation, and ocular pain. He has also worked on numerous projects in dry AMD, dry eye and Stargardt disease. Mr. Koester served as the Global Head of Biostatistics and Clinical Data Management at CIBA Vision/Novartis Ophthalmics and held senior-level positions at Novartis Pharmaceuticals, Acucela Inc., and Othera Pharmaceuticals.

  • Mark Nuttall | Quality Assurance

    Mark Nuttall, Quality Assurance, has been working in the pharmaceutical industry for more than 25 years with a primary focus on new drug development and commercialization. He has extensive experience in analytical and formulation development, quality assurance, and compilation of regulatory documentation. Mark has been heavily involved in more than 35 successful new product launches, both domestic and global, which includes eight NDAs. Mark was the VP of Quality at Astra Zeneca (formerly ZS Pharma) where he was a key member of the Lokelma development team. He was responsible for establishing a Quality System for two US facilities, and the design, buildout and expansion of the Quality functional areas. Prior to ZS Pharma, Mark held multiple roles at Reckitt Benckiser North America (Formerly Adams Respiratory Therapeutics) expanding the Mucinex product line from six core product to more than twenty that were successfully launched in multiple countries.

  • Dr. Michael Singer, MD

    Michael Singer M.D. is Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas. He is also the Director of Clinical Research at Medical Center Ophthalmology. Dr. Singer is a member of the Retina Society, the Macula Society, Club Jules Gonin, the American Academy of Ophthalmology and the American Society of Retina Specialists. Dr. Singer is the recipient of many awards, including the American Society of Retina Specialists Honor and Senior Honor award, the Achievement award of the American Academy of Ophthalmology, The Gary Thomas Award, Faculty of the Year of the F1000 Foundation, and Two ASRS Rhet Buckler Awards. Dr. Singer has been involved in well over 150 clinical trials and has presented research and taught courses both nationally and internationally. He is written numerous journal articles on all the medicines approved for retinal indications. In 2018 he was inducted into the Retina Hall of fame.

  • Dr. SriniVas R. Sadda, MD, FARVO

    SriniVas R. Sadda, MD, is the President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine. He received his medical degree from The Johns Hopkins University in Baltimore, Maryland. After an internship at the William Beaumont Hospital in Royal Oak, Michigan, he returned to Johns Hopkins University and the Wilmer Eye Institute in Baltimore for an ophthalmology residency as well as neuro-ophthalmology and medical retina fellowships.

    Dr Sadda’s major research interests include automated retinal image analysis, retinal substructure assessment, advanced retinal imaging technologies, and vision restoration approaches. His research has been consistently funded by the National Institutes of Health (NIH) and multiple private organizations including the Foundation Fighting Blindness, Research to Prevent Blindness, Foundation for Retinal Research, and the Macula Vision Research Foundation. He has organized multiple consensus efforts for the classification of various retinal disorders. Dr. Sadda has served as Principal Investigator for over 30 major clinical trials, and has led several international collaborative research programs. He is the founder and Emeritus Director of the Doheny Image Reading Center, one of the largest centralized reading centers in the world. He has more than 550 publications in peer-reviewed journals and over 300 published abstracts. He authored the first edition of the textbook Emerging Technologies in Retinal Disease, as well as 20 other book chapters. As an invited lecturer, he has given more than 450 presentations around the country and the world, including multiple named lectures. Dr. Sadda also serves as an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Graefe’s Archive for Clinical and Experimental Ophthalmology, Ophthalmology Retina, and Ophthalmology. He is also an editor of the 5th edition of the Ryan’s Retina textbook.  He regularly serves the NIH Center for Scientific Review on study section.

    Among Dr. Sadda’s awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, a Senior Achievement Award and Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, the Macula Society Young Investigator Award, Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award, The Macula Society Paul Henkind Lecture and Award, and American Society of Retina Specialists Young Investigator Award. He has also received the Silver Fellow designation from the Association for Research in Vision and Ophthalmology. He has been named to the Best Doctors of America list for several consecutive years.

  • Dr. Paul Yang, MD, PhD

    Dr. Paul Yang received doctorates in medicine and neurophysiology at Dartmouth Medical School, which was funded by an M.D./Ph.D. pre-doctoral award from the National Institutes of Health. He completed a residency and fellowship in ophthalmology at the Moran Eye Center in Salt Lake City, during which he first developed an interest in inflammatory eye diseases and degenerative retinal disorders. Thereafter, he pursued a fellowship in ocular immunology and uveitis at the Massachusetts Eye Research and Surgery Institution in Cambridge, Massachusetts, as well as a fellowship in ophthalmic genetics and inherited retinal degenerations at Casey Eye Institute in Portland, Oregon. He was funded by the Foundation Fighting Blindness (FFB) Clinical Research Fellowship Award, FFB Career Development Award, and NIH K08 to evaluate the effectiveness of mycophenolate as a neuroprotective agent in inherited retinal degenerations. For this pioneering work, he was awarded the 2015 ARVO/Alcon Early Career Clinician-Scientist Research Award. Dr. Yang is an assistant professor in ophthalmic genetics and immunology at the Casey Eye Institute (Oregon Health & Science University) where he specializes in patients with inherited retinal degenerations, autoimmune retinopathy, and gene therapy associated uveitis. He is a PI and sub-I on numerous gene therapy and neuroprotection clinical trials for inherited retinal degenerations. Dr. Yang continues to conduct translational research in his lab with the goal of bringing new medical treatments to the clinic for patients with inherited retinal degenerations.

  • Dr. Stephen H. Tsang, MD, PhD.

    Stephen H. Tsang, M.D, Ph.D. is an acclaimed geneticist in the care of individuals with retinal degenerations, and has been culturing embryonic stem (ES) cells since 1992 and created the first mouse model for a recessive form of retinitis pigmentosa (RP) by applying CRISPR genome engineering to ES cell technology in 1995. He successfully treated preclinical models of Pde6a, Pde6b, Mfrp, Rho, Cngb1 and autosomal recessive bestrophin retinopathies. He has expertise in designing and testing genome engineering strategies in pre-clinical models, developing patient-specific knock-in models, generating of patient cell lines and providing care to patients with a precision medicine approach. He is also leading efforts in FDA trials for gene therapies, including PDE6A, RAB geranylgeranyl transferase, RPGR, CNGB3, CNGA3 and ABCA4 retinopathies. He wrote 2 books: “Precision Medicine, CRISPR, and Genome Engineering: Moving from Association to Biology and Therapeutics.; and “Stem Cell Biology and Regenerative Medicine in Ophthalmology”, Springer Press, NY; and “Stem Cell Biology and Regenerative Medicine in Ophthalmology”, Springer Press, NY. He is an elected member of several honorary societies including the American Society for Clinical Investigation, Alcon Research Institute and American Ophthalmological Society. He is consistently named to various NIH study sections (DPVS standing member 2014-18).

  • Dr. Sai Chavala, MD |  Key Clinical Advisor

    Dr. Chavala is a clinician-surgeon-scientist, dedicated to innovation and development of novel treatments that improve the quality of life of patients. After obtaining MD, he completed residency/fellowship at Weill Medical College of Cornell University and Duke University. His research has been funded by NIH.

     

     

     

     

  • Vittorio Porciatti, DSc

    Vittorio Porciatti DSc is the James L. Knight Professorship of Ophthalmology, and Director and Vice Chair of Research at Bascom Palmer Eye Institute, University of Miami, where he also has secondary appointments at the Department of Biomedical Engineering and at the Neuroscience Program. He received his education in biological sciences and training in neurosciences in Pisa, Italy, where he also worked for many years as senior scientist at the Institute of Neurophysiology of the National Research Council (CNR) with secondary appointment at the Department of Ophthalmology, Catholic University, Rome, Italy. His translational research on the visual system has taken advantage of non-invasive electrophysiological tools for retinal ganglion cell function testing he pioneered and continuously developed. At the Bascom Palmer Eye Institute, he has developed two NIH-funded programs on retinal ganglion cell plasticity and early detection/restoration of visual function in patients with glaucoma and optic nerve disorders. 

  • Dr. Thomas Yorio, PhD

    Dr. Thomas Yorio is Provost Emeritus and a member of the North Texas Eye Research Institute at University of North Texas Health Science Center. He was Founding Dean of the Graduate School of Biomedical Sciences and served as Provost and Executive Vice President for Academic Affairs at UNTHSC. 

    He received his Ph.D. in Pharmacology from Mount Sinai School of Medicine in New York, where he remained for a brief Postdoctoral appointment as a National Science Foundation Fellow and a National Kidney Foundation Fellow. An ocular pharmacologist, Dr. Yorio has made many contributions to the area of glaucoma, with research over the last four decades focused in the areas on transport in aqueous humor dynamics, endothelin pharmacology in glaucoma and in identifying potential targets for neuroprotection. He has participated in numerous presentations at national and international symposia and has been a member of the Association in Research in Vision and Ophthalmology (ARVO) for over 40 years. Dr. Yorio has had numerous grant awards for his work in glaucoma pharmacology from a variety of sources including, the Department of Defense (DoD), National Eye Institutes (NEI), National Heart, Lung and Blood Institute, National Institute of General Medical Sciences, pharmaceutical industry and foundations.

    He has published more than 160 peer-reviewed research articles, reviews, and book chapters, and is co-editor of a textbook. He also serves as associate editor for several scientific journals and served as Editor in Chief of Investigative Ophthalmology and Visual Science and remains on its editorial board.

    Dr. Yorio is a Fellow of ARVO, where he also served as the Physiology and Pharmacology Trustee and as ARVO Vice President. He was honored two times with ARVO’s Distinguished Service Award and in 2019, was the recipient of ARVO’s Joanne G. Angle Service Award. As an active member of ARVO he served on the Finance Committee while a Trustee, the Diversity Initiatives Committee, and the Annual Meeting Program Committee.  Dr. Yorio is also a member of the ARVO Board of Governors and the Dowling Society of the ARVO Foundation. In addition to his ARVO membership he has also been an active member of the International Society for Eye Research (ISER) for more than 20 years and has chaired or helped organize several symposia for the ISER congress and is a recipient of the Ernst H. Barany Prize from ISER recognizing his contributions to ocular pharmacology. He has been selected as a Fellow in the Association for Ocular Pharmacology and Therapeutics where he served as President from 2015 to 2019 and now as Immediate Past President. He has been a member of AOPT since its inception and attended and presented at most of the AOPT conferences.